Clarification sought from Natco Pharma Ltd
The Exchange has sought clarification from Natco Pharma Ltd with respect to disclosure submitted by the Company December 16, 2014 titled "Allotment of Equity Shares on Preferential Basis other than Cash" Natco Pharma Ltd has been requested to submit its clarification to the Exchange with respect to the following in terms of Clause 36 of the Listing Agreement.... Allotment of Equity Shares on Preferential Basis other than Cash
Natco Pharma Ltd has informed BSE that the committee of Directors at a meeting held on December 16, 2014 allotted1,61,775 equity shares of Rs. 10/- each at a premium of Rs. 1190/- per share on preferential basis other than cash to the promoters of Natco Organics Limited. Press Release
Natco Pharma Ltd vide its letter dated December 12, 2014 has submitted to BSE a copy of Press Release. Press Release
Natco Pharma Ltd has informed BSE regarding a Press Release dated November 27, 2014 titled "Business Update". Results Press Release
Natco Pharma Ltd has submitted to BSE a copy of Results Press Release for the period ended September 30, 2014. Outcome of Board Meeting
Natco Pharma Ltd has informed BSE that the Board of Directors of the Company at its meeting held on November 12, 2014, inter alia, has taken on record the following:1. Mr. P S R K Prasad, Executive Vice President (Corporate Engineering Services) appointed as Additional Director of the Company who will be in the wholetime employment of the Company.2. Mr. S V V N Appa Rao, Vice President (Finance & Accounts) appointed as Interim (Chief Financial Officer) of the Company. Announces Q2 results & Limited Review Report for the Quarter ended September 30, 2014
Natco Pharma Ltd has announced the following results for the quarter ended September 30, 2014:The Unaudited Standalone results for the Quarter ended September 30, 2014The Company has posted a net profit of Rs. 348.00 million for the quarter ended September 30, 2014 as compared to Rs. 286.90 million for the quarter ended September 30, 2013. Total Income has increased from Rs. 1518.30 million for the quarter ended September 30, 2013... Q2 results on Nov 12, 2014
Natco Pharma Ltd has informed BSE that a meeting of the Board of Directors of the Company will be held on November 12, 2014, inter alia, to consider the unaudited financial Results for the quarter ended September 30, 2014 (Q2) and related matters.Further, TRADING WINDOW for dealing in the securities of the company will be closed from October 31, 2014 to November 14, 2014 (both days inclusive). Trading window will be opened from November 15, 2014. Demise of Director
Natco Pharma Ltd has informed BSE that Dr. P. Bhaskara Narayana, Director and Chief Financial Officer of the Company passed away on October 21, 2014. NATCO announces USFDA Tentative Approval for Armodafinil 50mg, 150mg, and 250mg Tablets
Natco Pharma Ltd has informed BSE regarding a Press Release dated October 21, 2014 titled "NATCO announces USFDA Tentative Approval for Armodafinil 50mg, 150mg, and 250mg Tablets".